ES104: Potential First-in-Class Anti-VEGFxDLL4 Bispecific Antibody
ES104 is a bispecific antibody targeting both vascular endothelial growth factor (VEGF) and Delta-like ligand 4/Notch (DLL4), two critical pathways driving angiogenesis and tumor vascularization. VEGF blockade reduces tumor vessel formation, which is synergistically enhanced by DLL4 inhibition, leading to decreased vessel perfusion. Dual blockade of VEGF and DLL4 is designed to overcome multi-VEGF resistance.